'USFDA nod for Zaynich a major boost'
Wockhardt's new antibiotic, Zaynich, has received US FDA approval. This marks a significant milestone as it is the first novel drug from India to achieve this. Zaynich targets severe drug-resistant infections. The company anticipates substantial global sales, with patent protection extending to 2038. This development is expected to create a major market opportunity for Wockhardt.
Wockhardt's new antibiotic, Zaynich, has received US FDA approval. This marks a significant milestone as it is the first novel drug from India to achieve this. Zaynich targets severe drug-resistant infections. The company anticipates substantial global sales, with patent protection extending to 2038. This development is expected to create a major market opportunity for Wockhardt.
